Today I would like to talk about a common problem in clinical trials in progressive disease (e.g. cancer) with an time-to-event endpoint (eg progression or death), which concerns the interpretation of interim results with low maturity. Low maturity can be caused: “by design”: by selection of a timepoint where only a limited fraction of events … Continue reading Interim analysis of a time-to-event endpoint with low maturity